Lack of association between the functional CX3CR1 polymorphism V249I and hepatocellular carcinoma

Oncology Reports

Volumn 13, Issue 5, 2005, Pages 957-963

  Mühlbauer, Marcus ^a   Ringel, Susanne ^a   Hartmann, Arndt ^a   Lallinger, Gertrud ^a   Weiss, Thomas S ^a   Gäbele, Erwin ^a   Wünsch, Peter H ^b   Schölmerich, Jürgen ^a   Hellerbrand, Claus ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

Author keywords

Chemokines; CX3CR1; Fractalkine; Hepatocellular carcinoma; Risk factor

Indexed keywords

CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PRIMER DNA;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; FEMALE; GENETICS; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AMINO ACID SUBSTITUTION; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CHEMOKINE; RETROSPECTIVE STUDIES;

EID: 25144477513     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.5.957     Document Type: Article

References (44)

1. Bosch FX and Munoz N: Epidemiology of hepatocellular cancer. In: Liver Cell Carcinoma. Bansch P, Keppler D and Weber G (eds). Kluwer Academics, Dordrecht, pp3-12, 1989.
2. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750 1999. (Pubitemid 29114292)
3. Yu AS and Keeffe EB: Management of hepatocellular carcinoma. Rev Gastroenterol Disord 3: 8-24, 2003. (Pubitemid 36335933)
4. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
5. Bogenrieder T and Herlyn M: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22: 6524-653, 2003.
6. Yoong KF, McNab G, Hubscher SG and Adams DH: Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 160: 3978-3988, 1998. (Pubitemid 28176106)
7. Bone-Larson CL, Simpson KJ, Colletti LM, Lukacs NW, Chen SC, Lira S, Kunkel SL and Hogaboam CM: The role of chemokines in the immunopathology of the liver. Immunol Rev 177: 8-20, 2000.
8. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM and Kunkel SL: Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin Sci 104: 47-63, 2003. (Pubitemid 36249923)
9. Lu P, Nakamoto Y, Nemoto-Sasaki Y, Fujii C, Wang H, Hashii M, Ohmoto Y, Kaneko S, Kobayashi K and Mukaida N: Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. Am J Pathol 162: 1249-1258, 2003. (Pubitemid 36350669)
10. Yamauchi K, Akbar SM, Horiike N, Michitaka K and Onji M: Increased serum levels of macrophage inflammatory protein-3alpha in hepatocellular carcinoma: relationship with clinical factors and prognostic importance during therapy. Int J Mol Med 11: 601-605, 2003.
11. Akiba J, Yano H, Ogasawara S, Higaki K and Kojiro M: Expression and function of inteiieukin-8 in human hepatocellular carcinoma. Int J Oncol 18: 257-264, 2001.
12. Shin EC, Choi YH, Kim JS, Kim SJ and Park JH: Expression patterns of cytokines and chemokines genes in human hepatoma cells. Yonsei Med J 43: 657-664, 2002. (Pubitemid 35282889)
13. Mitra P, De A, Ethier MF, Mimori K, Kodys K, Shibuta K, Mori M, Madison JM, Miller-Graziano C and Barnard GF: Loss of chemokine SDF-1 alpha-mediated CXCR4 signalling and receptor internalization in human hepatoma cell line HepG2. Cell Signal 13: 311-319, 2001. (Pubitemid 32448948)
14. Tsuchiyama T, Kaneko S, Nakamoto Y, Sakai Y, Honda M, Mukaida N and Kobayashi K: Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther 10: 260-269, 2003. (Pubitemid 36423107)
15. Sakai Y, Kaneko S, Nakamoto Y, Kagaya T, Mukaida N and Kobayashi K: Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma. Cancer Gene Ther 8: 695-704, 2001. (Pubitemid 32983125)
16. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644, 1997.
17. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ and Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530, 1997. (Pubitemid 27508241)
18. Chen YM, Tu CJ, Hung KY, Wu KD, Tsai TJ and Hsieh BS: Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappaB down-regulation. Br J Pharmacol 138: 950-958, 2003.
19. Ludwig A, Berkhout T, Moores K, Groot P and Chapman G: Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 168: 604-612, 2002. (Pubitemid 34049559)
20. Fujimoto K, Imaizumi T, Yoshida H, Takanashi S, Okumura K and Satoh K: Interferon-gamma stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am J Respir Cell Mol Biol 25: 233-238, 2001. (Pubitemid 32752450)
21. Brand S, Sakaguchi T, Gu X, Colgan SP and Reinecker HC: Fractalkine-mediated signals regulate cell-survival and immune-modulatory responses in intestinal epithelial cells. Gastroenterology 122: 166-177, 2002. (Pubitemid 34049205)
22. Efsen E, Grappone C, De Franco RM, Milani S, Romanelli RG, Bonacchi A, Caligiuri A, Failli P, Annunziato F, Pagliai G, Pinzani M, Laffi G, Gentilini P and Marra F: Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 37: 39-47, 2002. (Pubitemid 34713053)
23. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D'Agostino RB, O'Donnell CJ, Patel DD and Murphy PM: Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 111: 1241-1250, 2003. (Pubitemid 36519941)
24. Moatti D, Faure S, Fumeron F, Amara M, Seknadji P, McDermott DH, Debre P, Aumont MC, Murphy PM, De Prost D and Combadiere C: Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97: 1925-1928, 2001. (Pubitemid 32239068)
25. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, Theodorou I and Combadiere C: Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287: 2274-2277, 2000. (Pubitemid 30177034)
26. Hirohashi S, Ishak KG, Kojiro M, Wanless IR, Theise ND, Tsukuma H, Blum HE, Deugnier Y, Laurent Puig P, Fischer HP and Sakamoto M: Hepatocellular carcinoma. In: Pathology and Genetics of Tumours of the Digestive System. Hamilton SR and Aaltonen LR (eds). IARC Press, Lyon, pp159-172, 2000.
27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M and Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520, 1994. (Pubitemid 24166476)
28. Bosserhoff AK, Moser M, Scholmerich J, Buettner R and Hellerbrand C: Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes. J Biol Chem 278: 15225-15231, 2003. (Pubitemid 36799858)
29. Nesbit M, Schaider H, Miller TH and Herlyn M: Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in non-tumorigenic melanoma cells. J Immunol 166: 6483-6490, 2001. (Pubitemid 32467185)
30. Nakashima E, Mukaida N, Kubota Y, Kuno K, Yasumoto K, Ichimura F, Nakanishi I, Miyasaka M and Matsushima K: Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm Res 12: 1598-1604, 1995. (Pubitemid 26004682)
31. Huang S, Singh RK, Xie K, Gutman M, Berry KK, Bucana CD, Fidler IJ and Bar-Eli M: Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 39: 231-238, 1994. (Pubitemid 24316764)
32. Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW and Gabuzda D: Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 197: 1701-1707, 2003. (Pubitemid 36745345)
33. Yuh K, Shimizu M, Aoyama S, Ichihara I, Watanabe H, Okumura M and Kikuchi M: Immunological analysis and characterization of lymphocyte subsets in specimens of human hepatocellular carcinomas and metastatic liver cancers. Cancer Immunol Immunother 28: 1-8, 1989.
34. Guo J, Zhang M, Wang B, Yuan Z, Guo Z, Chen T, Yu Y, Qin Z and Cao X: Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 103: 212-220, 2003. (Pubitemid 35461513)
35. Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, Ogawa M, Nakamura Y and Arakawa H: Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res 60: 3722-3726, 2000. (Pubitemid 32204558)
36. Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB and Conlon PJ: The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol 165: 397-403, 2000. (Pubitemid 30429532)
37. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K and Dean NM: Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 18: 862-867, 2000. (Pubitemid 30640912)
38. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY and Yoo NJ: Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 32: 250-256, 2001. (Pubitemid 32246797)
39. Tanaka Y, Furuta T, Suzuki S, Orito E, Yeo AE, Hirashima N, Sugauchi F, Ueda R and Mizokami M: Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. J Infect Dis 187: 1822-1825, 2003. (Pubitemid 36667895)
40. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y and Omata M: Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37: 65-71, 2003. (Pubitemid 36042146)
41. Huang YS, Chern HD, Wu JC, Chao Y, Huang YH, Chang FY and Lee SD: Polymorphism of the N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma. Am J Gastroenterol 98: 1417-1422, 2003. (Pubitemid 36741543)
42. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S and Katoh T: Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol 126: 355-360, 2003. (Pubitemid 36963198)
43. Silvestri L, Sonzogni L, De Silvestri A, Gritti C, Foti L, Zavaglia C, Leveri M, Cividini A, Mondelli MU, Civardi E and Silini EM: CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 104: 310-317, 2003. (Pubitemid 36249813)
44. McDermott DH, Halcox JP, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, Quyyumi AA and Murphy PM: Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 89: 401-407, 2001. (Pubitemid 34132655)